Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Hobnail variant of papillary thyroid carcinoma: an institutional case series and molecular profile.

Lubitz CC, Economopoulos KP, Pawlak AC, Lynch K, Dias-Santagata D, Faquin WC, Sadow PM.

Thyroid. 2014 Jun;24(6):958-65. doi: 10.1089/thy.2013.0573.

2.
3.

Concomitant RAS, RET/PTC, or BRAF mutations in advanced stage of papillary thyroid carcinoma.

Zou M, Baitei EY, Alzahrani AS, BinHumaid FS, Alkhafaji D, Al-Rijjal RA, Meyer BF, Shi Y.

Thyroid. 2014 Aug;24(8):1256-66. doi: 10.1089/thy.2013.0610.

4.

Concomitant BRAF(V600E) mutation and RET/PTC rearrangement is a frequent occurrence in papillary thyroid carcinoma.

Guerra A, Zeppa P, Bifulco M, Vitale M.

Thyroid. 2014 Feb;24(2):254-9. doi: 10.1089/thy.2013.0235.

PMID:
23806056
5.

Tall cell variant of papillary thyroid microcarcinoma: clinicopathologic features with BRAF(V600E) mutational analysis.

Bernstein J, Virk RK, Hui P, Prasad A, Westra WH, Tallini G, Adeniran AJ, Udelsman R, Sasaki CT, Roman SA, Sosa JA, Prasad ML.

Thyroid. 2013 Dec;23(12):1525-31. doi: 10.1089/thy.2013.0154.

PMID:
23682579
6.

Papillary thyroid carcinoma with prominent hobnail features: a new aggressive variant of moderately differentiated papillary carcinoma. A clinicopathologic, immunohistochemical, and molecular study of eight cases.

Asioli S, Erickson LA, Sebo TJ, Zhang J, Jin L, Thompson GB, Lloyd RV.

Am J Surg Pathol. 2010 Jan;34(1):44-52. doi: 10.1097/PAS.0b013e3181c46677.

PMID:
19956062
7.

Tumor genotype determines phenotype and disease-related outcomes in thyroid cancer: a study of 1510 patients.

Yip L, Nikiforova MN, Yoo JY, McCoy KL, Stang MT, Armstrong MJ, Nicholson KJ, Ohori NP, Coyne C, Hodak SP, Ferris RL, LeBeau SO, Nikiforov YE, Carty SE.

Ann Surg. 2015 Sep;262(3):519-25; discussion 524-5. doi: 10.1097/SLA.0000000000001420.

8.

Mutational and clinico-pathological analysis of papillary thyroid carcinoma in Serbia.

Stanojevic B, Dzodic R, Saenko V, Milovanovic Z, Pupic G, Zivkovic O, Markovic I, Djurisic I, Buta M, Dimitrijevic B, Rogounovitch T, Mitsutake N, Mine M, Shibata Y, Nakashima M, Yamashita S.

Endocr J. 2011;58(5):381-93.

9.

NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States.

Prasad ML, Vyas M, Horne MJ, Virk RK, Morotti R, Liu Z, Tallini G, Nikiforova MN, Christison-Lagay ER, Udelsman R, Dinauer CA, Nikiforov YE.

Cancer. 2016 Apr 1;122(7):1097-107. doi: 10.1002/cncr.29887.

PMID:
26784937
10.

Epidermal growth factor receptor overexpression is a marker for adverse pathologic features in papillary thyroid carcinoma.

Fisher KE, Jani JC, Fisher SB, Foulks C, Hill CE, Weber CJ, Cohen C, Sharma J.

J Surg Res. 2013 Nov;185(1):217-24. doi: 10.1016/j.jss.2013.05.003.

11.

Both BRAF V600E mutation and older age (≥ 65 years) are associated with recurrent papillary thyroid cancer.

Howell GM, Carty SE, Armstrong MJ, Lebeau SO, Hodak SP, Coyne C, Stang MT, McCoy KL, Nikiforova MN, Nikiforov YE, Yip L.

Ann Surg Oncol. 2011 Dec;18(13):3566-71. doi: 10.1245/s10434-011-1781-5.

PMID:
21594703
12.

BRAF V600E does not predict aggressive features of pediatric papillary thyroid carcinoma.

Givens DJ, Buchmann LO, Agarwal AM, Grimmer JF, Hunt JP.

Laryngoscope. 2014 Sep;124(9):E389-93. doi: 10.1002/lary.24668.

PMID:
24604709
13.

The BRAF(V600E) mutation influences the short- and medium-term outcomes of classic papillary thyroid cancer, but is not an independent predictor of unfavorable outcome.

Russo M, Malandrino P, Nicolosi ML, Manusia M, Marturano I, Trovato MA, Pellegriti G, Frasca F, Vigneri R.

Thyroid. 2014 Aug;24(8):1267-74. doi: 10.1089/thy.2013.0675.

PMID:
24787545
14.

Fine-needle aspiration molecular analysis for the diagnosis of papillary thyroid carcinoma through BRAF V600E mutation and RET/PTC rearrangement.

Pizzolanti G, Russo L, Richiusa P, Bronte V, Nuara RB, Rodolico V, Amato MC, Smeraldi L, Sisto PS, Nucera M, Bommarito A, Citarrella R, Lo Coco R, Cabibi D, Lo Coco A, Frasca F, Gulotta G, Latteri MA, Modica G, Galluzzo A, Giordano C.

Thyroid. 2007 Nov;17(11):1109-15.

PMID:
17727338
15.

Absence of BRAF, NRAS, KRAS, HRAS mutations, and RET/PTC gene rearrangements distinguishes dominant nodules in Hashimoto thyroiditis from papillary thyroid carcinomas.

Sadow PM, Heinrich MC, Corless CL, Fletcher JA, Nosé V.

Endocr Pathol. 2010 Jun;21(2):73-9. doi: 10.1007/s12022-009-9101-3.

PMID:
20012784
16.

Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.

Quiros RM, Ding HG, Gattuso P, Prinz RA, Xu X.

Cancer. 2005 Jun 1;103(11):2261-8. Review.

17.

[Correlation between BRAF V600E mutation and clinicopathologic features of papillary thyroid carcinoma].

Lu H, Qiu T, Ying J, Guo C, Lyn N.

Zhonghua Bing Li Xue Za Zhi. 2014 Dec;43(12):794-8. Chinese.

PMID:
25623974
18.

Clinicopathologic implications of the BRAF(V600E) mutation in papillary thyroid cancer: a subgroup analysis of 3130 cases in a single center.

Lim JY, Hong SW, Lee YS, Kim BW, Park CS, Chang HS, Cho JY.

Thyroid. 2013 Nov;23(11):1423-30. doi: 10.1089/thy.2013.0036.

PMID:
23496275
19.

[Frequency of RET/PTC rearrangement and somatic BRAF mutation in papillary thyroid cancer].

Rumiantsev PO, Zaletaev DV, Vasil'ev EV, Saenko VA, Il'in AA, Rumiantseva UV, Abrosimov AIu, Medvedev VS.

Vopr Onkol. 2006;52(2):145-9. Russian.

PMID:
17195637
20.

Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer.

Xing M, Alzahrani AS, Carson KA, Viola D, Elisei R, Bendlova B, Yip L, Mian C, Vianello F, Tuttle RM, Robenshtok E, Fagin JA, Puxeddu E, Fugazzola L, Czarniecka A, Jarzab B, O'Neill CJ, Sywak MS, Lam AK, Riesco-Eizaguirre G, Santisteban P, Nakayama H, Tufano RP, Pai SI, Zeiger MA, Westra WH, Clark DP, Clifton-Bligh R, Sidransky D, Ladenson PW, Sykorova V.

JAMA. 2013 Apr 10;309(14):1493-501. doi: 10.1001/jama.2013.3190.

Supplemental Content

Support Center